The following Structured Product Label (SPL) was submitted to the FDA by Hikma Specialty Usa Inc. for the product Kloxxado (NDC 59467-679). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 important dosage and administration instructions, 2.2 dosing in adult and pediatric patients, 3 dosage forms and strengths, 4 contraindications, 5.1 risk of recurrent respiratory and central nervous system depression, 5.2 risk of limited efficacy with partial agonists or mixed agonist/antagonists, 5.3 precipitation of severe opioid withdrawal, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
KLOXXADO is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.
KLOXXADO is intended for immediate administration as emergency therapy in settings where opioids may be present.
KLOXXADO is not a substitute for emergency medical care.
Initial Dosing
The recommended initial dose of KLOXXADO in adult and pediatric patients is one spray delivered by intranasal administration into one nostril, which delivers 8 mg of naloxone hydrochloride to adult or pediatric patients.
Repeat Dosing
Seek emergency medical assistance as soon as possible, after administering the first dose of KLOXXADO.
If the desired response is not obtained after 2 or 3 minutes, administer an additional dose using a new KLOXXADO in alternate nostril. If there is still no response and additional doses are available, administer additional doses of KLOXXADO every 2 to 3 minutes, alternating nostrils and using a new KLOXXADO, until emergency medical assistance arrives. The requirement for repeat doses of KLOXXADO depends upon the amount, type, and route of administration of the opioid being antagonized.
If the patient responds to KLOXXADO and subsequently relapses back into respiratory depression before emergency assistance arrives, administer an additional dose using a new KLOXXADO, in the opposite nostril, and continue surveillance of the patient.
Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
Reversal of respiratory depression by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete and require repeated administration of KLOXXADO using a new nasal spray [see Warnings and Precautions(5.2)].
KLOXXADO is supplied as a single-dose, intranasal spray containing 8 mg of naloxone hydrochloride (equivalent to 7.2 mg naloxone) in 0.1 mL. It is a clear, colorless to yellow solution filled into a clear glass vial, stoppered and fitted with a unit-dose nasal spray device.
KLOXXADO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients in KLOXXADO.
The duration of action of most opioids may exceed that of KLOXXADO resulting in a return of respiratory and/or central nervous system depression after an initial improvement in symptoms. Therefore, it is necessary to seek emergency assistance immediately after administration of the first dose of KLOXXADO and to keep the patient under continued surveillance. Administer additional doses of KLOXXADO if the patient is not adequately responding or responds and then relapses back into respiratory depression, as necessary [see Dosage and Administration (2.2)]. Additional supportive and/or resuscitative measure may be helpful while awaiting emergency medical assistance.
Reversal of respiratory depression by partial agonists or mixed/antagonists such as buprenorphine and pentazocine may be incomplete. Larger or repeat doses of naloxone hydrochloride may be required to antagonize buprenorphine because the latter has a long duration of action due to its slow rate of binding and subsequent slow dissociation from the opioid receptor [see Dosage and Administration (2.2)]. Buprenorphine antagonism is characterized by a gradual onset of the reversal effects and a decreased duration of action of the normally prolonged respiratory depression.
The use of KLOXXADO in patients who are opioid-dependent may precipitate opioid withdrawal characterized by the following signs and symptoms: body aches, diarrhea, tachycardia, fever, runny nose, sneezing, piloerection, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may include the following signs and symptoms: convulsion, excessive crying, and hyperactive reflexes. Monitor the patient for the development of the signs and symptoms of opioid withdrawal.
Abrupt postoperative reversal of opioid depression after using naloxone hydrochloride may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as sequelae of these events. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor patients with pre-existing cardiac disease or patients who have received medications with potential adverse cardiovascular effects for hypotension, ventricular tachycardia or fibrillation, and pulmonary edema in an appropriate healthcare setting. It has been suggested that the pathogenesis of pulmonary edema associated with the use of naloxone hydrochloride is similar to neurogenic pulmonary edema, i.e., a centrally mediated massive catecholamine response leading to a dramatic shift of blood volume into the pulmonary vascular bed resulting in increased hydrostatic pressures.
There may be clinical settings, particularly the postpartum period in neonates with known or suspected exposure to maternal opioid use, where it is preferable to avoid the abrupt precipitation of opioid withdrawal symptoms. In these settings, consider use of an alternative, naloxone-containing product that can be titrated to effect and, where applicable, dosed according to weight [see Use in Specific Population (8.4)].
The following serious adverse reactions are discussed elsewhere in the labeling:
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In two pharmacokinetic studies a total of 47 healthy adult volunteers were exposed to a single dose of KLOXXADO, one spray in one nostril. The following adverse reactions were reported in two subjects each: abdominal pain, asthenia, dizziness, headache, nasal discomfort, and presyncope. On local tissue assessments for nasal irritation, signs of nasal inflammation and nasal congestion were observed.
The following adverse events have been identified during the post-approval use of naloxone hydrochloride injection in the postoperative setting. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as sequelae of these events. Excessive doses of naloxone hydrochloride in postoperative patients have resulted in significant reversal of analgesia and have caused agitation.
Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated an acute withdrawal syndrome. Signs and symptoms have included: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, tachycardia. In some patients, there was aggressive behavior upon abrupt reversal of an opioid overdose. In the neonate, opioid withdrawal has included: convulsions, excessive crying, hyperactive reflexes [see Warnings and Precautions (5.3)].
The following most frequently reported events (in decreasing frequency) have been identified primarily during post-approval use of naloxone hydrochloride (all routes of administration): withdrawal syndrome, vomiting, nonresponsiveness to stimuli, drug ineffective, agitation, somnolence, and loss of consciousness.
Risk Summary
Available data from retrospective cohort studies on naloxone use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Naloxone may precipitate opioid withdrawal in the pregnant woman and fetus [see Warnings and Precautions (5.3) and Clinical Considerations]. In animal reproduction studies, no embryotoxic or teratogenic effects were observed in mice and rats treated with naloxone hydrochloride during the period of organogenesis at doses equivalent to 3-times and 6-times, respectively, a human dose of 16 mg/day (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations
Maternal and Fetal/Neonatal Adverse Reactions
Naloxone hydrochloride crosses the placenta, and may precipitate withdrawal in the fetus, as well as in the opioid-dependent mother [see Warnings and Precautions (5.3)]. The fetus should be evaluated for signs of distress after KLOXXADO is used. Careful monitoring is needed until the fetus and mother are stabilized.
Data
Animal Data
Naloxone hydrochloride was administered during organogenesis to mice and rats at doses 3-times and 6-times, respectively, a human dose of 16 mg (from two nasal sprays of KLOXXADO) based on body surface area comparison. These studies demonstrated no embryotoxic or teratogenic effects due to naloxone hydrochloride.
Risk Summary
There is no information regarding the presence of naloxone in human milk, the effects of naloxone on the breastfed infant or on milk production. Studies in nursing mothers have shown that naloxone does not affect prolactin or oxytocin hormone levels. Naloxone is minimally orally available and is unlikely to affect the breastfed infant.
The safety and effectiveness of KLOXXADO has been established in pediatric patients of all ages for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Use of naloxone hydrochloride in pediatric patients is supported by evidence from adult bioavailability studies with additional evidence from the reported safe and effective use of other naloxone hydrochloride products. No pediatric studies were conducted for KLOXXADO.
Absorption of naloxone hydrochloride following intranasal administration in pediatric patients may be erratic or delayed. Even when the opiate-intoxicated pediatric patient responds appropriately to naloxone hydrochloride, he/she must be carefully monitored for at least 24 hours, as a relapse may occur as naloxone hydrochloride is metabolized.
In opioid-dependent pediatric patients, (including neonates), administration of naloxone hydrochloride may result in an abrupt and complete reversal of opioid effects, precipitating an acute opioid withdrawal syndrome. There may be clinical settings, particularly the postpartum period in neonates with known or suspected exposure to maternal opioid use, where it is preferable to avoid the abrupt precipitation of opioid withdrawal symptoms. Unlike acute opioid withdrawal in adults, acute opioid withdrawal in neonates manifesting as seizures may be life-threatening if not recognized and properly treated. Other signs and symptoms in neonates may include excessive crying and hyperactive reflexes. In these settings where it may be preferable to avoid the abrupt precipitation of acute opioid withdrawal symptoms, consider use of an alternative, naloxone hydrochloride product that can be dosed according to weight and titrated to effect [see Warnings and Precautions (5.3)].
Also, in situations where the primary concern is for infants at risk for opioid overdose, consider whether the availability of alternate naloxone-containing products may be better suited than KLOXXADO.
Juvenile Animal Study
In a juvenile animal study, male and female juvenile rats were administered a single intranasal dose of saline, vehicle consisting of 20% alcohol and 5% propylene glycol, or naloxone (123 mg/kg, 185 mg/kg, and 246 mg/kg) on postnatal day 7 (PND 7). There were no test article-related findings on sexual maturation, neuroapoptosis, or on a limited number of neurocognitive endpoints which included social interactions as well as learning and memory. The no-effect dose level for neurodevelopmental toxicity was the high dose tested, which is 6.8-times a neonate dose from two nasal sprays of KLOXXADO based on body surface area comparison and a neonate weight of 2.5 kg.
Clinical studies of KLOXXADO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
KLOXXADO (naloxone hydrochloride) nasal spray is an opioid antagonist supplied in a pre-filled intranasal device designed to deliver a single dose of 8 mg of naloxone hydrochloride (equivalent to 7.2 mg naloxone) in 0.1mL.
Chemically, naloxone hydrochloride is the hydrochloride salt of 17-allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride with molecular weight of 363.84 g/mol.
Its molecular formula is C19H21NO4.HCl, and it has the following chemical structure, as shown below.
Image-chemical-structure-usp.jpg (Image Chemical Structure Usp)
Naloxone hydrochloride occurs as a white to slightly off-white powder, and is soluble in water, in dilute acids, and in strong alkali; slightly soluble in alcohol; practically insoluble in ether and in chloroform.
The inactive ingredients in KLOXXADO include: dehydrated alcohol (20% (w/w)), edetate disodium dihydrate, propylene glycol, purified water, and sodium hydroxide and hydrochloric acid to adjust pH. The pH range is from 4.0 to 5.5.
Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Administration of naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.
When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within two minutes. The time to onset of action is shorter for intravenous compared to subcutaneous or intramuscular routes of administration. The duration of action is dependent upon the dose and route of administration of naloxone hydrochloride.
In two pharmacokinetic studies in up to 24 healthy adult volunteers for each study, the bioavailability (BA) of a single 8 mg dose (one spray) of KLOXXADO was compared to a single 0.4 mg intramuscular dose and a single 2 mg intravenous dose of naloxone. Naloxone plasma concentration versus time profiles are shown in Figure 1. The pharmacokinetic parameters of naloxone are summarized in Table 1.
Figure 1: Mean ± SD Plasma Concentration-Time Profiles of Naloxone Following A Single Dose of Intranasal versus Intramuscular/Intravenous Administration in Healthy Subjects. (A:0-4 h and B: 0-30 min.)
Figure-1(a)-naloxone-hcl-ns-8mg-with-stand-dev (Image 02)
Figure-1(b)-naloxone-hcl-ns-8mg-with-stand-dev (Image 03)
Table 1: Mean (CV%) Plasma Pharmacokinetic Parameters of Naloxone Following a Single Dose of Intranasal and Intramuscular/Intravenous Administration in Healthy Subjects
| Parameter | KLOXXADO 8 mg | Intramuscular Injection 0.4 mg | Intravenous Injection 2 mg | ||
|---|---|---|---|---|---|
Study | Study I | Study II | Study I | Study II | Study II |
N | 24 | 23 N=23 due to one subject withdrawal. | 24 | 23 | 24 |
Tmax(h) Tmax reported as median (minimum – maximum). | 0.25 | 0.25 | 0.25 | 0.25 | NA |
Cmax (ng/mL) | 12.3 (55.4) | 12.8 (37.0) | 0.876 (36.7) | 0.910 (36.8) | 26.2 (82.4) Cmax of Intravenous Injection 2 mg was observed value from the first sampling time of 2 minutes post-dose. |
AUClast | 18.0 (29.6) | 18.4 (33.4) | 1.82 (24.0) | 1.87 (24.7) | 12.7 (27.6) |
AUC0-inf(ng•h/mL) | 16.7 (31.9) N=15 | 19.0 (32.7) N=19 | 1.94 (20.9) N=22 for AUC0-inf and t1/2 | 1.95 (21.9) | 12.8 (27.5) |
t1/2 (h) | 2.69 (69.9) | 1.76 (39.7) | 1.41 (20.0) | 1.40 (38.9) | 1.22 (16.4) |
Dose normalized Relative BA (%) | 41.6 | 47.4 | 100 | 100 | NA |
Dose normalized Absolute BA (%) | NA | 36.6 | NA | 77.2 | 100 |
NA= Not applicable | |||||
Absorption
The median Tmax (15 min) for naloxone following administration of a single dose of 8 mg KLOXXADO nasal spray was the same as following administration of a single intramuscular dose of 0.4 mg naloxone hydrochloride.
The dose normalized relative bioavailability of naloxone following administration of a single dose of 8 mg KLOXXADO was 42 to 47% as compared to following administration of a single intramuscular dose of 0.4 mg naloxone hydrochloride. The absolute bioavailability of naloxone following administration of a single dose of 8 mg KLOXXADO nasal spray was 37% as compared to following administration of a single intravenous dose of 2 mg naloxone hydrochloride.
Distribution
Following parenteral administration, naloxone is distributed in the body and readily crosses the placenta. Plasma protein binding occurs but is relatively weak. Plasma albumin is the major binding constitute, but significant binding of naloxone also occurs to plasma constituents other than albumin. It is not known whether naloxone is excreted into human milk.
Elimination
Following a single intranasal administration of KLOXXADO, the mean half-life (t1/2) of naloxone in plasma was 1.8 (39.7% CV) to 2.7 (69.6% CV) hours. The mean t1/2 was 1.4 (38.9% CV) to 1.4 (20.0% CV) hours for a 0.4 mg naloxone hydrochloride intramuscular injection and 1.2 (16.4% CV) hours for a 2 mg naloxone hydrochloride intravenous injection. In a neonatal study of naloxone hydrochloride the mean (±SD) plasma half-life was observed to be 3.1 ± 0.5 hours.
Metabolism
Naloxone hydrochloride is metabolized in the liver, primarily by glucuronide conjugation, with naloxone-3-glucoronide as the major metabolite.
Excretion
After an oral or intravenous dose, about 25 to 40% of naloxone is excreted as metabolites in urine within 6 hours, about 50% in 24 hours, and 60 to 70% in 72 hours.
Carcinogenesis
Studies in animals to assess the carcinogenic potential of naloxone have not been conducted.
Mutagenesis
Naloxone was weakly positive in the Ames mutagenicity and in the in vitro human lymphocyte chromosome aberration test but was negative in the in vitro Chinese hamster V79 cell HGPRT mutagenicity assay and in the in vivo rat bone marrow chromosome aberration study.
Impairment of Fertility
Reproduction studies conducted in mice and rats at doses 3-times and 6-times, respectively, a human dose of 16 mg/day (from two nasal sprays of KLOXXADO) based on body surface area comparison, demonstrated no adverse effects on fertility of naloxone hydrochloride.
KLOXXADO (naloxone hydrochloride) nasal spray is a clear, colorless to yellow solution supplied in a single-dose spray device that consists of a stoppered glass vial encased in a container holder fitted with a spray actuator, cannula, and spray pin. It delivers a single dose of 8 mg of naloxone hydrochloride (equivalent to 7.2 mg naloxone) in 0.1 mL. Each KLOXXADO carton contains two individual blisters sealed with a paper backing with a “peel off” feature. The carton contains abbreviated instructions-for-use printed on the back. In addition, a quick instructions leaflet is attached to the bottom of each individual blister.
1 Carton containing two nasal spray devices: NDC# 59467-679-01
Not made with natural rubber latex.
Storage and Handling
Store KLOXXADO in the blister and cartons provided.
Store at 20 to 25°C (68°F to 77°F), with excursions permitted to 40°C (104°F) and to 5°C (41°F). Do not store at or above 40°C (104°F). Do not freeze. Protect from light.
KLOXXADO freezes at temperatures below -15°C (5°F). If this happens, the device will not spray. If KLOXXADO is frozen and is needed in an emergency, do NOT wait for KLOXXADO to thaw. Get emergency medical help right away. However, KLOXXADO may be thawed by allowing it to sit at room temperature for 15 minutes, and it may still be used if it has been thawed after being previously frozen.
Advise the patient and family members or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Recognition of Opioid Overdose
Inform patients and their family members or caregivers about how to recognize the signs and symptoms of an opioid overdose such as the following:
Risk of Recurrent Respiratory and Central Nervous System Depression
Instruct patients and their family members or caregivers that, because the duration of action of most opioids may exceed that of KLOXXADO, they must seek immediate emergency medical assistance after the first dose of KLOXXADO and keep the patient under continued surveillance [see Dosage and Administration (2.2), Warnings and Precautions (5.3)].
Limited Efficacy for/with Partial Agonists or Mixed Agonist/Antagonists
Instruct patients and their family members or caregivers that the reversal of respiratory depression caused by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete and may require higher doses of naloxone hydrochloride or repeated administration of KLOXXADO, using a new nasal spray each time [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].
Precipitation of Severe Opioid Withdrawal
Instruct patients and their family members or caregivers that the use of KLOXXADO in patients who are opioid dependent may precipitate opioid withdrawal [see Warnings and Precautions (5.3), Adverse Reactions (6)].
Administration Instructions
Instruct patients and their family members or caregivers to:
Distr. by: Hikma
Specialty USA Inc.
Columbus, OH 43228
C50001066/01
Revised April 2021
KLOXXADOTM is a trademark of Hikma Pharmaceuticals USA Inc.
PATIENT INFORMATION KLOXXADOTM (Kloks-AH-doh) (naloxone hydrochloride) nasal spray | |
You and your family members or caregivers should read this Patient Information leaflet before an opioid emergency happens. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. | |
What is the most important information I should know about KLOXXADO nasal spray? KLOXXADO nasal spray is used to temporarily reverse the effects of opioid medicines. The medicine in KLOXXADO nasal spray has no effect in people who are not taking opioid medicines. Always carry KLOXXADO nasal spray with you in case of an opioid emergency.
| |
What is KLOXXADO nasal spray?
| |
Do not use KLOXXADO nasal spray:
| |
Before using KLOXXADO nasal spray, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. | |
How should I use KLOXXADO nasal spray? Read the “Instructions for Use” at the end of this Patient Information leaflet for detailed information about the right way to use KLOXXADO nasal spray.
| |
What are the possible side effects of KLOXXADO nasal spray? KLOXXADO nasal spray may cause serious side effects, including:
| |
|
|
In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be lifethreatening if not treated the right way. Signs and symptoms include: seizures, crying more than usual, and increased reflexes. The most common side effects of KLOXXADO in adults include: stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort and a feeling like you are going to faint. These are not all of the possible side effects of KLOXXADO nasal spray. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |
How should I store KLOXXADO nasal spray?
Keep KLOXXADO nasal spray and all medicines out of the reach of children. | |
General information about the safe and effective use of KLOXXADO nasal spray. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KLOXXADO nasal spray for a condition for which it was not prescribed. You can ask your pharmacist or healthcare provider for information about KLOXXADO nasal spray that is written for health professionals. | |
What are the ingredients in KLOXXADO nasal spray? Active ingredient: naloxone hydrochloride Inactive ingredients: dehydrated alcohol (20% (w/w)),edetate disodium dihydrate, propylene glycol, purified water, and sodium hydroxide and hydrochloric acid to adjust pH. KLOXXADO nasal spray is not made with natural rubber latex. | |
Distributed by: Hikma Specialty USA Inc. Columbus, OH 43228 C50001066/02 KLOXXADOTM nasal spray is a trademark of Hikma Pharmaceuticals USA Inc. For more information, visit www.Hikma.com or call Hikma Specialty USA Inc. at 1-800-962-8364. | |
This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: April 2021
INSTRUCTIONS FOR USE KLOXXADOTM (Kloks-AH-doh) (naloxone hydrochloride) nasal spray You and your family members or caregivers should read the Instructions for Use that comes with KLOXXADO nasal spray before using it. Talk to your healthcare provider if you and your family members or caregivers have any questions about the use of KLOXXADO nasal spray. Use KLOXXADO nasal spray for known or suspected opioid overdose in adults and children. Important: For use in the nose only.
| |
How to use KLOXXADO nasal spray:
Note: KLOXXADO freezes at temperatures below 5°F (-15°C). If this |  Peeling-back-blister-with-zoom-of-triangle (Image 01)  Ifu-image-2-proper-way-to-hold-device (Image 05)  Ifu-image-3-support-back-of-neck (Image 06)  Ifu-image-4-insert-tip-into-nostril (Image 07)  Ifu-image-5-place-patient-on-their-side (Image 08)  Ifu-image-6-clock-2-3-minutes (Image 09) |
How should I store KLOXXADO nasal spray?
Distributed by: Hikma Specialty USA Inc. Columbus, OH 43228 C50001066/01 KLOXXADOTM is a trademark of Hikma Pharmaceuticals USA Inc. For more information, visit www.Hikma.com or call Hikma Specialty USA Inc. at 1-800-962-8364. | |
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Issued: April 2021
KLOXXADOTM (naloxone HCl) nasal spray, 8 mg - Folding Carton
NDC # 59467-679-01
Kloxxado-fc-c50001063-02-k03 (Image 04)
* Please review the disclaimer below.
